AbbVie (ABBV) said it’s not in talks to acquire cancer drugmakerRevolution Medicines (RVMD), reported both Bloomberg and Reuters. “AbbVie is not in discussions with RevMed,” a spokesperson for AbbVie is quoted as said in a statement to Bloomberg. The Wall Street Journal reported earlier that AbbVie was in “advanced” talks to purchase Revolution.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie says not in discussions with Revolution Medicines, Reuters reports
- Erasca up 66% after WSJ report on AbbVie interest in Revolution Medicines
- Revolution Medicines extends gain to 29% after resuming trading
- Revolution Medicines near deal to be bought by AbbVie, WSJ says
- AbbVie near deal to buy Revolution Medicines, WSJ reports